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Dear Editor,
We read with interest the paper by Saniee et al, who found that 
at Shariati Hospital (Tehran, Iran), among dyspeptic patients 
referred to the endoscopy unit for upper gastrointestinal 
(GI) endoscopy during the period 2010-2017, Helicobacter 
pylori resistance to metronidazole (MTZ) increased from 
33%–55.6% to 79.4% over time, to clarithromycin (CLR) 
increased from 1.4–7.3% to 34.4%, to tetracycline (TET) 
increased from 0–38.1% to 38.5%, to amoxicillin (AMX) 
increased from 1.4%–7.3% to 27.1% and to furazolidone 
(FRZ) increased from 0%–4.5% to 23.9%.1
We would like to highlight several points regarding these 
results.
Helicobacter pylori resistance is defined as primary when 
patients have never been treated for this bacterium and 
secondary when patients have already been treated. Thus, 
these two concepts express in the first scenario a correlation 
with a degree of antibiotic consumption and in the second 
scenario the consequence of the fact that users fail to take 
their full course of prescribed antibiotic treatment. In the 
latter scenario, the bacteria subsequently remain untouched 
gaining more strength against the antibiotics.2  
Considering primary resistance, based on a multicentre 
study published in 2013, the resistance rate of H. pylori in 
Europe was 34.9% for MTZ, 17.5% for CLR, 0.9% for 
TET and 0.7% for AMX. The same study assessed the fits 
of models and the degree of ecological association between 
antibiotic use and resistance data. A significant association 
was found between fluoroquinolone use and the proportion 
of levofloxacin resistance in H. pylori and between the use of 
long-acting macrolides and clarithromycin resistance.3 In the 
paper by Saniee et al, it is unclear if patients are at their first 
treatment or are experienced.1
Furthermore, we are astonished with the high rate of 
resistance to AMX (27.1%) when compared to Europe 
(0.7%). The same is true for the resistance to TET. It would 
be interesting to ask the authors if they have data on AMX 
and TET consumption in their area. This data would be 
alarming in case of primary resistance.
Finally, we have a comment. Normally, the main reason 
of H. pylori resistance to antibiotics is supposed to be poor 
patient compliance. Recently, in China4 and in Italy,5 two 
examples of poor medical compliance have been reported. In 
our study, in the period from first of January 2014–to first 
of January 2016, we found that the repetition of the same 
treatment after a failure (a well-known wrong doctor strategy) 
occurred in 15.1% of patients versus the 3.9% of the period 
2004–2006 (P < 0.0001). There was no difference comparing 
generalists, gastroenterologists and internists. Moreover, the 
repetition prevalence among gastroenterologists ranged from 
0% in the period 2004–2006 to 18.2% in the period 2014–
2016 (P = 0.088).5 
In conclusion, the work by Saniee et al, beyond updating 
the data on H. pylori resistance to antibiotics in their area, 
stimulates a new field of research investigating the reasons 
for this increase. 
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